Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $40.6 million.

  • Keros Therapeutics' Shares Outstanding (Weighted Average) rose 806.75% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 806.75%. This contributed to the annual value of $37.4 million for FY2024, which is 2713.52% up from last year.
  • Per Keros Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $40.6 million for Q3 2025, which was up 806.75% from $40.6 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $40.6 million in Q3 2025 and a low of $23.2 million during Q1 2021
  • In the last 5 years, Keros Therapeutics' Shares Outstanding (Weighted Average) had a median value of $29.4 million in 2023 and averaged $30.4 million.
  • Per our database at Business Quant, Keros Therapeutics' Shares Outstanding (Weighted Average) soared by 83515.54% in 2021 and then surged by 321.08% in 2022.
  • Quarter analysis of 5 years shows Keros Therapeutics' Shares Outstanding (Weighted Average) stood at $23.3 million in 2021, then rose by 8.17% to $25.2 million in 2022, then rose by 16.66% to $29.4 million in 2023, then rose by 27.14% to $37.4 million in 2024, then grew by 8.51% to $40.6 million in 2025.
  • Its last three reported values are $40.6 million in Q3 2025, $40.6 million for Q2 2025, and $40.6 million during Q1 2025.